vailsymposium

How does scientific research turn into cancer treatments? Who is doing the research and who is funding the research? What areas of cancer research are being funded and why? What is the government’s role in funding research and directing research policy and how does that impact the development of new treatments for cancer?

Join Dr. William Dahut, the Chief Scientific Officer of the American Cancer Society, and Steve Curtis, the Interim Managing Director of BrightEdge, the venture capital arm of the American Cancer Society, as they walk us through the research ecosystem including: governmental vs. non-governmental driven-research and funding; the process of translating research into treatments for patients; and the relationship between public policy and the impact in fighting cancer from prevention through survivorship.

Curtis is the Interim Managing Director of BrightEdge and VP, Innovation and Impact Investing for American Cancer Society. Prior to ACS, Steve managed MPM Capital’s Oncology Innovations Fund, a hybrid venture/philanthropy investment collaboration with Dana-Farber Cancer Institute. He also has experience with Eli Lilly and Company, Bioscience Ventures group within 2M Companies, and Reata Pharmaceuticals.

Dahut is an internationally recognized physician-investigator, managing more than $400 million in research funding and guiding the American Cancer Society’s efforts to enhance and focus their research program, concentrate their priorities and working with key partners. He has authored nearly 250 publications in peer-reviewed journals and pioneered treatments in prostate and other cancers.